DongKoo Bio & Pharma Co., Ltd.

A006620

KR7006620009

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 27/06/2024 BST			5-day change	1st Jan Change
6,900 ^KRW	+0.29%		-2.27%	+21.91%

05-17	Qurient Co., Ltd. announced that it has received KRW 13.499996307 billion in funding from DongKoo Bio & Pharma Co., Ltd.	CI
05-02	Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on November 2, 2023.	CI

Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on November 2, 2023.

May 02, 2024 at 08:10 am

From April 1, 2024 to May 2, 2024, the company has repurchased 226,555 shares, representing 0.82% for KRW 1,479.05 million. With this, the company has completed the repurchase of 321,701 shares, representing 1.17% for KRW 1,998.73 million under the buyback announced on November 2, 2023.

Latest news about DongKoo Bio & Pharma Co., Ltd.

Qurient Co., Ltd. announced that it has received KRW 13.499996307 billion in funding from DongKoo Bio & Pharma Co., Ltd.	05-16	CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on November 2, 2023.	05-02	CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on November 2, 2023.	05-02	CI
DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback announced on November 2, 2023, has expired with 321,701 shares, representing 1.17% for KRW 1,998.73 million.	05-01	CI
Qurient Co., Ltd. announced that it expects to receive KRW 13.499998256 billion in funding from DongKoo Bio & Pharma Co., Ltd. and another investor	04-11	CI
OTOM Co., Ltd. announced that it has received KRW 2 billion in funding from DongKoo Bio & Pharma Co., Ltd.	03-05	CI
HDT Co., Ltd announced that it expects to receive KRW 2 billion in funding from DongKoo Bio & Pharma Co., Ltd.	02-27	CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on November 2, 2023.	02-02	CI
DongKoo Bio & Pharma Co., Ltd. announces an Equity Buyback for KRW 2,000 million worth of its shares.	11-02	CI
DongKoo Bio&Pharma Co., Ltd. authorizes a Buyback Plan.	11-01	CI
DongKoo Bio & Pharma Co., Ltd.(KOSDAQ:A006620) dropped from S&P Global BMI Index	18/09/23	CI
DongKoo Bio & Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	20/03/23	CI
HLB Pharmaceutical Co., Ltd announced that it has received KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd.	09/08/22	CI
HLB Pharmaceutical Co., Ltd announced that it expects to receive KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd.	08/08/22	CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on January 28, 2022.	27/07/22	CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on January 28, 2022.	27/07/22	CI
DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback announced on January 28, 2022, has expired with 416,327 shares, representing 1.49% for KRW 2,995.1 million.	26/07/22	CI
Tranche Update on DongKoo Bio&Pharma Co., Ltd.'s Equity Buyback Plan announced on January 28, 2022.	28/04/22	CI
Tranche Update on DongKoo Bio&Pharma Co., Ltd.'s Equity Buyback Plan announced on October 14, 2021.	13/04/22	CI
DongKoo Bio&Pharma Co., Ltd.'s Equity Buyback announced on October 14, 2021, has expired with 251,612 shares, representing 0.89% for KRW 1,997.79 million.	12/04/22	CI
DongKoo Bio&Pharma Co., Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares.	28/01/22	CI
DongKoo Bio&Pharma Co., Ltd. authorizes a Buyback Plan.	27/01/22	CI
Valted Seq, Inc. announced that it has received $12.99 million in funding from DongKoo Bio&Pharma Co., Ltd., Loftyrock Investment Co., Ltd., OV Principal Investments, LLC and other investors	26/01/22	CI
Valted Seq, Inc. announced that it has received $10.5 million in funding from DongKoo Bio&Pharma Co., Ltd. and other investors	01/11/21	CI
DongKoo Bio&Pharma Co., Ltd. announces an Equity Buyback for KRW 2,000 million worth of its shares.	14/10/21	CI

Chart DongKoo Bio & Pharma Co., Ltd.

Duration

Period

More charts

Company Profile

Dongkoo Bio&Pharma Co.,Ltd. is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The major products include antihistamines, topical steroids, therapeutic agents for prostatitis, treatments for benign prostatic hyperplasia, atherosclerotic agents, and antibiotics, among others. The Company is involved in contract manufacturing organization business. It manufactures and sells therapeutic for osteoporosis, antiviral agents, erectile dysfunction treatments, hepatic disease agents; painkillers; gum treatments. In addition, the Company is engaged in the manufacturing and sale of medical devices and cosmetics. The Company distributes its products within the domestic market and to overseas markets, including America and Europe.

Sector

Pharmaceuticals

Calendar

18/05/2025 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DONGKOO BIO & PHARMA CO., LTD.	+21.91%	137M
ELI LILLY AND COMPANY	+55.32%	815B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
ROCHE HOLDING AG	+2.04%	224B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B